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LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND SYMPTOMS OF
ETHNICALLY DIVERSE BLOOD AND MARROW TRANSPLANTATION PA-
TIENTS
Neumann, J.L.1, Cohen, M.Z.1, Mendoza, T.1, Giralt, S.1,
Cleeland, C.1 1The University of Texas MD Anderson Cancer Center,
Houston, TX.
Several investigators in the nursing, medicine, and psychology
have examined the effects of BMT on quality of life (QOL).
Several studies indicated a signiﬁcant reduction in QOL and per-
sistent symptoms of fatigue, insomnia, anorexia, and nausea in the
ﬁrst year after BMT (Kopp, Schweigkoﬂer, Holzner, et al. 1998,
Winer, Lindley, Hardee, et al. 1999, Hann, Jacobsen, Martin, et al.
1997). The long-term impact of BMT on QOL has been examined
(Andrykowski, Carpenter, et al. 1997, Andrykowski, Brady, et al.
1995 and Andrykowski, Bishop, Hahn, Cella, et al, 2005). None of
these studies examined differences of QOL and symptoms among
ethnically diverse groups of patients.
In our recently completed National Institute of Health sponsored
study, the correlation of quality of life and symptoms were evalu-
ated at multiple time points over the course of 100 days in 164
African-Americans (n24), Hispanic (n38) and non-minority
(n102) patients. The Functional Assessment of Cancer Therapy
(FACT-BMT) measuring quality of life and MD Anderson Symp-
tom Inventory (MDASI) assessing symptoms and symptom inter-
ference with life were used in the study. Other variables examined
included disease, type of transplant, age, graft vs. host disease
(GVHD) and survival. Preliminary results indicate that patients
receiving myeloablative regimen experienced severe symptoms
such as fatigue (p0.02) and pain (p0.03) and poorer QOL
(p0.01) across time. Symptom severity correlates (r -0.59 to
-0.75) with QOL across time. In addition, there were no signiﬁcant
differences in symptom severity, symptom interference and ECOG
performance status between Hispanic and African-Americans over
time. There were signiﬁcant differences in symptom severity,
symptom interference, and ECOG performance across time in
both minority and non-minority groups of BMT patients. Results
of this study add to the knowledge related to symptom clusters and
QOL with this treatment modality and help to guide development
of relevant patient teaching material.
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CHOICE OF DIET AS PART OF TREATMENT FOR GI GVHD
Niangar, G.A.1 1MD Anderson Cancer Center, Houston, TX.
Purpose: To determine which diet can be used to help decrease
amount of diarrhea as associated with GI GVHD (gastrointestinal
graft-versus-host-disease)
Methods: Based on our institution’s guidelines for nutritional
support of patient’s undergoing GI GVHD after allogeneic stem
cell transplant.
Result: There are 4 levels of diet that is used for GI GVHD;
patients are placed on these diets depending on the severity of their
symptoms.
Conclusion: GI GVHD is a major complication after allogeneic
hematopoeitic stem cell transplantation. This can cause diarrhea,
nausea, vomiting, abdominal cramping and pain. With large
amounts of diarrhea, for instance in Stage 4 GI GVHD (severe
cramps with or without ileus), the physician may ask the patient not
to eat or drink for a few days to allow the GI (gastrointestinal) tract
to rest. In MD Anderson a four-stage diet, intended for stem cell
transplant patients who experience symptoms from graft-versus-
host disease is utilized. Dietary recommendation varies from noth-
ing-by-mouth for the most severe (Stage 4) to limiting high fat and
ﬁber foods for 500-1000 ml diarrhea (Stage 1). Calories, proteins,
vitamins and minerals are provided through initiation of total
parenteral nutrition (TPN) to meet their nutritional needs while
on diet restriction.
While nutrition is monitored, multidrug therapies are started as
well, such as steroids, antithymoglobulin and other newer agents
like Inﬂiximab. The patient’s compliance to the diet prescribed is
of utmost importance to help minimize symptoms of GI GVHD.
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REDUCING CENTRAL VENOUS CATHETER RELATED BLOODSTREAM
INFECTIONS IN CHILDREN WITH CANCER
Norville, R.1, Horvath, B.1, Lee, D.1, Hyde, A.1, Gregurich, M.A.1,
Hilburn, J.1, Versalovic, J.2, Mueller, B.2, Stark, J.2, Hockenberry, M.2
1Texas Children’s Hospital, Houston, TX; 2Baylor College of Medicine,
Houston, TX.
The purpose of this study was to determine whether a compre-
hensive educational program inﬂuenced the incidence of hub col-
onization of central venous catheters (CVC) and bloodstream in-
fection (BSI) rates in children with cancer.
CVC infections rates in children with cancer range from 1.0 to
4.58 per 1000 catheter days. CVC hub sites provide bacterial access
to the bloodstream and hub colonization rates in adults vary from
29%-38%. Previous studies show that increasing staff and paren-
teral awareness with education that emphasizes aseptic technique
can decrease catheter infection rates.
A total of 121 registered nurses attended a one-hour educational
program that included a didactic component, a hands-on clinical
simulation and pre- and post-education learning assessments. Prior
to the education program, 51 catheter hub cultures were obtained
from a convenience sample of 27 children with cancer. Cultures
were obtained by swabbing the threaded area of the catheter hub
after removing the injection cap. A semi-quantitative culture for
bacteria and fungus was obtained. Thirty-nine catheter hub cul-
tures were obtained within 3.5 months after the education program
from 20 children. The mean age of the patients was 8.2 years; 78%
were diagnosed with leukemia and 22% with solid tumors. Sur-
veillance of monthly catheter-related bloodstream infections was
tracked for a six-month period for bone marrow transplant (BMT)
and general oncology patients upon completion of the staff edu-
cation program.
Pre- and post-education assessment of nursing staff revealed the
post-test mean score of 86.5% was signiﬁcantly better than the
pre-test mean score of 72% (p0.001). Prior to the education
program, 57% of the hubs were culture positive and after the
educational program the proportion of culture positive hubs was
reduced to 36%. The two-proportion test procedure showed sig-
niﬁcant reduction in culture positive hubs following the interven-
tion (p0.043). Post-intervention, BSI rates reduced from 5.59 to
3.35 per 1000 catheter days for BMT patients and from 4.89 to
3.03 per 1000 catheter days for general oncology patients. A log-
linear model showed a signiﬁcant reduction (p0.001) in infection
rates following the educational program for both patient popula-
tions.
The results of this study indicate that a comprehensive educa-
tional program increases nurses’ knowledge of CVC care and
reduces CVC hub colonization and catheter-related bloodstream
infections in children with cancer.
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STEM CELL TRANSPLANTATION FOR OSTEOPETROSIS: ONE CENTER’S
EXPERIENCE
O’Connor, M.P.1, Myers, K.1, Melone, M.1, Lehmann, L.1 1Dana
Farber Childrens Cancer Care, Boston, MA.
Osteopetrosis is a rare metabolic disorder characterized by ab-
normally dense bones due to a defect in the osteoclasts, the cells
responsible for bone resorption. Osteopetrosis generally presents
in infancy. Infants are brought to medical attention through inci-
dental skeletal radiographs and hypocalcemic seizures. Patients
with osteopetrosis are at high risk for morbidity and mortality.
They may present with pancytopenia, cranial nerve abnormalities
and respiratory difﬁculties. Pancytopenia is caused by the overpro-
duction of bone, which results in obliteration of the marrow cavity.
Loss of vision and hearing is a direct result of narrowing of the
cranial foramina. Respiratory difﬁculties are thought to occur due
to narrowing of the nasal passages and the relatively immobile rib
cage restricting lung movement. Osteoclasts are derived from he-
matopoietic stem cells and thus, by providing donor osteoclasts,
allogeneic stem cell transplant (SCT) can be curative.
From 1997 though 2005, ﬁve patients with osteopetrosis received
allogeneic stem cell transplants at Dana Farber Children’s Cancer
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Care in Boston, MA. At the time of SCT, these patients ranged in
age from 2 to 11 months old. Conditioning regimens prior to
transplant all contained a combination of intravenous busulfan,
cytoxan, and an additional lymphocytotoxic agent such as ﬂudara-
bine, alemtuzumab or anti-thymocyte globulin. Three of the ﬁve
patients required intubation at a median of day 4 post transplant.
All but one patient was successfully extubated at a median of 31
days post transplant. That patient was removed from life support
due to multi-organ failure at day  44 having not yet engrafted.
The remaining four patients engrafted at a median of 40 days post
transplant. Two died after day  100, one of a bacterial infection
and the other of enteroviral myocarditis. Two long-term survivors
are well and developing appropriately at 9 months and 33 months
post-transplant. Infants with osteopetrosis seem to have an in-
creased risk of pulmonary and infectious complications. Mothers of
these patients are recently post-partum and families are often far
from home at a tertiary care center. Nursing implications for the
care of the osteopetrosis patient during SCT include vigilant mon-
itoring of respiratory status, vital signs and laboratory results.
Extensive family support and education regarding the disease and
the transplant process is also essential for the care of these children
and their families.
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CARDIAC AMYLOIDOSIS AND STEM CELL TRANSPLANTATION: WHAT
NURSES NEED TO KNOW
Oliver, T.D.1 1The University of Texas MD Anderson Cancer Center,
Houston, TX.
Primary (AL) amyloidosis with cardiac involvement is commonly
seen in patients with multiple myeloma (MM). More than twenty-
ﬁve percent of patients with cardiac amyloidosis will develop heart
failure. Thus, as more patients with MM seek stem cell transplan-
tation for treatment of their disease, health care providers can
expect to see more complications related to cardiac amyloidosis. In
order to better prepare nurses caring for MM patients with cardiac
amyloidosis, a teaching poster has been developed that increases
stem cell transplant nurses’ knowledge about cardiac amyloidosis.
The educational poster focuses on improving early recognition
and management of AL amyloidosis through increased nursing
knowledge of signs and symptoms of cardiac amyloidosis. Early
signs of cardiac amyloid involvement include dyspnea, fatigue,
peripheral edema, systolic murmur, dysrhythmia, and postural hy-
potension. Nurses should be prepared to adjust patient daily rou-
tines in order to provide supportive treatment for hypotension and
congestive heart failure. It is important for nurses to become more
aware of the signs and symptoms of AL amyloidosis in order to
alert primary care teams of changes in patient condition, inquire
about telemetry monitoring and cardiology consults. Therefore,
the ultimate goals of increasing knowledge among nurses caring for
stem cell transplant patients with cardiac amyloidosis are better
symptom management, appropriate multidisciplinary participation
in care, and positive patient outcomes. These goals are attainable
when nurses more completely understand their patients’ medical
conditions and increased knowledge may be evaluated through
positive post-test results after presentation of the educational
poster.
A case presentation of a patient with multiple myeloma and
cardiac amyloidosis who underwent stem cell transplantation will
illustrate these teaching points and nursing issues as well as high-
light the ethics surrounding stem cell transplantation and cardiac
amyloidosis.
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PRIMARY CARE IN A TERTIARY SETTING OF STEM CELL TRANSPLAN-
TATION
Rhodes, B.A.1 1M.D.Anderson Cancer Center, Houston, TX.
The traditional role of a nurse practitioner is in a primary care
setting; however nurse practitioners are prepared by education and
clinical training to function in a variety of settings. This poster will
explore how a nurse practitioner in a major cancer referral center
provides comprehensive care and has a positive impact on patients
and staff in the complex setting of hematopoietic transplantation.
Setting: Major Cancer Referral Center, Department of Stem
Cell Transplantation and Cellular Therapy
Staff: Adult Nurse Practitioner (ANP), RNs, LVNs, Pharma-
cists, Physicians, and Patient Service Coordinators
Roles of Nurse Practitioner: Patient Care - Provides quality,
evidence-based patient care. Patient population includes a variety
of complex cancer patients with multiple myeloma, lymphoma,
leukemia, aplastic anemia, melanoma, glioblastoma, and neuroblas-
toma that are undergoing autologous or allogeneic hematopoeitic
cell transplantation or participating in vaccination clinical trials.
ANP performs comprehensive health assessments, identiﬁes nor-
mal and abnormal characteristics, develops treatment plan, initiates
appropriate care and continuously evaluates outcomes. Collabo-
rates with multidisciplinary health care team of nurses, physicians,
pharmacist, social worker, case manager, nutritionist and chaplain.
Educator - Provides education to hospital and nursing staff,
other healthcare workers, students, patients, and patient’s family
members regarding prevention and management of symptoms re-
lated to the transplant process. Conducts lectures and inservices on
a variety of transplant-related topics within the hospital/clinic
environment as well as at local and national conferences.
Research and Quality Improvement - Participates in a variety
of research protocols including stem cell research and development
of new therapies for transplant patients. Serves as an active member
of the quality improvement committee of stem cell and cellular
therapy that monitors for trends, outcomes, and adverse effects to
improve processes and positively affect patient care.
Outcomes - High level of patient satisfaction, documented by
quarterly patient satisfaction surveys
Decreased number of hospitals admissions and length of hospital
stays
Increased revenue of outpatient clinic.
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SURVEILLANCE, EVALUATION AND MANAGEMENT OF PASSENGER
LYMPHOCYTE SYNDROME
Rice, J.M.1, Sirilla, J.A.1, Krugh, D.W.1, Crawford, R.1,
Benson, D.M.1, Devine, S.M.1 1Ohio State University James Cancer
Hospital and Solove Research Institute, Columbus, OH.
Sudden immune hemolysis in the setting of ABO and non-ABO
mismatched allogeneic stem cell transplantation is a potentially
life-threatening complication that requires early recognition and a
multidisciplinary care team to deliver immediate lifesaving mea-
sures. The BMT Program at The Ohio State University James
Cancer Hospital developed a Plan of Care providing guidelines for
surveillance, evaluation and management of immune hemolysis
related to Passenger Lymphocyte Syndrome.
Surveillance consists of a direct antiglobulin testing (DAT) per-
formed on day 7, 14 and 21 and monitoring of donor anti-
body in the patient’s ABO reverse typing or antibody screen. If a
donor has a clinically signiﬁcant RBC antibody, the patient is
antigen typed for the respective antigen.
Discovery of a positive DAT and the presence of the donor’s
antibody, an initial hemolytic evaluation is performed including:
lactate dehydrogenase (LD), total and direct bilirubin (BILI), hap-
toglobin and hemoglobin/hematocrit (H/H).
If the hemolytic evaluation is negative, H/H every 12 hours and
BILI, LD daily are performed until day 28 to monitor for
hemolysis.
If the hemolytic evaluation is positive without signiﬁcant hemo-
lysis (i.e., 2 g/dL drop in hemoglobin), H/H every 12 hours and
BILI, LD, HAPT, urinalysis daily are performed until day 28.
RBC exchange is considered in the setting of laboratory evidence
of hemolysis when: a patient has related, signiﬁcant physical symp-
toms, a  2 g/dL in hemoglobin in 24 hour period, or impairment
of creatinine clearance and/or hemoglobinuria.
Order sets have been implemented through electronic ordering
pathways. Ongoing, prospective evaluation of the strategy is un-
derway.
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